{"id":1026,"date":"2020-06-22T14:24:00","date_gmt":"2020-06-22T14:24:00","guid":{"rendered":"https:\/\/quantadt.wpengine.com\/us\/?p=1026"},"modified":"2023-09-21T16:27:23","modified_gmt":"2023-09-21T16:27:23","slug":"quanta-appoints-hooman-hakami-as-non-executive-director","status":"publish","type":"post","link":"https:\/\/quantadt.com\/us\/quanta-appoints-hooman-hakami-as-non-executive-director\/","title":{"rendered":"Quanta Appoints Hooman Hakami as Non-Executive Director"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>22 July 2020<\/strong>: Quanta Dialysis Technologies Ltd, a British medical technology innovation company, today announces the appointment of Hooman Hakami to the Company\u2019s Board as an independent Non-Executive Director, with immediate effect.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hooman has 30 years of leadership experience, including senior positions at two of the world\u2019s largest medical devices companies. At Medtronic, he was Executive Vice President and President of the Diabetes Group and prior to that he spent more than 20 years at General Electric, where he was a Company Officer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Johan de Ruiter, Chairman of the board said, &#8220;I am very pleased to welcome Hooman to the Quanta Board. His commercial experience in introducing disruptive technologies will be a large asset to the Company as we continue with the rollout and preparation of US market launch of SC+, Quanta\u2019s small, simple and versatile haemodialysis system. I look forward to working with Hooman as we expand production of SC+ over the coming months, improving the lives of haemodialysis patients&#8221;.<\/p>\n\n\n            <div id=\"quanta-appoints-hooman-hakami-as-non-executive-director-testimonials\" class=\"  pt-20 overflow-hidden pb-20\">\n                <div class=\"__viewport\">\n                    <div class=\"__container flex flex-col gap-8\">\n                        <div class=\"__slide flex flex-col lg:flex-row items-center rounded-lg bg-white px-8 py-20 gap-4 basis-full lg:basis-8\/12 grow-0 shrink-0 relative border border-2\">\n                            <div class=\"absolute -top-8 left-1\/2 -translate-x-1\/2 text-[15rem] text-secondary italic leading-none\">\"<\/div>\n                                                        <div class=\"flex flex-col\">\n                                <div class=\"-mb-6\">\n                                    <!-- wp:paragraph -->\n<p>It is a pleasure to join the Quanta Board. Kidney failure is a growing clinical issue, but the way it has been treated hasn\u2019t fundamentally changed in almost 20 years. As we have seen with the COVID-19 crisis, patients need and want remote, point-of-care solutions. Quanta\u2019s haemodialysis technology and its elegant SC+ system have been designed with this in mind. Because the system is engineered for freedom it is extremely well positioned to drive a transformation in kidney failure management. I look forward to working with the Board and the senior leadership team to achieve the full potential of SC+ and help improve the lives of as many patients as possible.<\/p>\n<!-- \/wp:paragraph -->                                <\/div>\n                                <p class=\"font-bold mt-4 !mb-0\">Hooman Hakami<\/p>\n                                <p class=\"text-xs !mb-0\">Non-Executive Director<\/p>\n                                <p class=\"text-xs !mb-0\">Quanta<\/p>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n                <\/div>\n            <\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>22 July 2020: Quanta Dialysis Technologies Ltd, a British medical technology innovation company, today announces the appointment of Hooman Hakami to the Company\u2019s Board as an independent Non-Executive Director, with immediate effect. Hooman has 30 years of leadership experience, including senior positions at two of the world\u2019s largest medical devices companies. At Medtronic, he was [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1028,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-1026","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles"],"acf":[],"_links":{"self":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/posts\/1026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/comments?post=1026"}],"version-history":[{"count":0,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/posts\/1026\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/media\/1028"}],"wp:attachment":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/media?parent=1026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/categories?post=1026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/tags?post=1026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}